Use the Search Fields to Find Information
Page 56 of 373
THC and CBD produce divergent effects on perception and panic behaviours via distinct cortical molecular pathways
Please use this link to access this publication. Abstract Clinical and pre-clinical evidence demonstrates divergent psychotropic effects of THC vs. CBD. While THC can induce
March 25, 2024
THC and CBD affect metabolic syndrome parameters including microbiome in mice fed high fat-cholesterol diet
Abstract Background: Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic syndrome, which often includes obesity, diabetes, and dyslipidemia. Several studies in mice and humans
February 12, 2024
Text message-delivered cannabis use disorder treatment with young adults: A large randomized clinical trial
Please use this link to access this publication. Abstract Background Two scientific and clinical challenges for treating cannabis use disorder (CUD) are developing efficacious treatments
February 15, 2026
Tetrahydrocannabinol vape-associated cannabis arteritis in a patient with minimal tobacco exposure
Abstract Thromboangiitis obliterans (TAO) is an inflammatory vasculopathy that often presents in young men with substantial tobacco use. Cannabis arteritis is the cannabis-associated counterpart, but
February 8, 2026
Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study
Please use this link to access this publication. Abstract Background & Aims Delta-9-tetrahydrocannabinol (THC) is the most abundant cannabinoid from the plant Cannabis sativa. There is only equivocal
August 5, 2024
Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial
Please use this link to access this publication. Abstract Objective: To determine whether differences in disability status, spasticity severity, and spasticity duration at treatment start in
July 1, 2024
Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions
Abstract Combination tetrahydrocannabinol (THC)/cannabidiol (CBD) medicines or CBD-only medicines are prospective treatments for chronic pain, stress, anxiety, depression, and insomnia. THC and CBD increase signaling
January 15, 2024
Tetrahydrocannabinol and cannabidiol as an oromucosal spray in a 1:1 ratio: a therapeutic option for patients with central post-stroke pain syndrome?
Please use this link to access this publication. Abstract Central pain after stroke due to brainstem infarction is very rare. Treatment is difficult and specific
May 20, 2024
Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information
Please use this link to access this publication. Abstract Introduction Cannabis and agonists of the brain cannabinoid receptor (CB1R) produce acute memory impairments in humans.
August 5, 2024
Tetrahydrocannabinol (THC) Exacerbates Inflammatory Bowel Disease in Adolescent and Adult Female Rats
Abstract Inflammatory Bowel Disease (IBD) is a life-long disorder that often begins between the ages of 15 and 30. Anecdotal reports suggest cannabinoids may be
April 30, 2024
Page 56 of 373